Syros: Pivotal Trial In MDS Ongoing
Andrew Brookes/Cultura via Getty Images
Syros Pharmaceuticals (SYRS) didn’t start out well. Its 2016 IPO was a bust, and that was followed by the failure of its lead drug SY-1425 in a phase 2 monotherapy trial in AML. That was in 2017, and then once again…
